boxhill wrote:Julia123's signature indicated that she is MSS, not MSI.
Julia123 wrote:boxhill wrote:Julia123's signature indicated that she is MSS, not MSI.
does this mean that a mutation test is not needed? I understand that this is not Lynch syndrome.
Drugs used in colorectal cancer, with ther FDA approval dates
1962 5-FU (Fluorouracil Injection) - no restrictions
1998 Xeloda (Capecitabine) - no restrictions
2000 Camptosar (Irinotecan Hydrochloride) - no restrictions
2004 Avastin (Bevacizumab) - mCRC 1st line+
2004 Eloxatin (Oxaliplatin) - no restrictions
2004 Erbitux (Cetuximab) - mCRC 1st line+, KRAS wild type only
2006 Vectibix (Panitumumab) - mCRC 1st line+, KRAS wild type only
2012 Keytruda (Pembrolizumab) - mCRC 1st line, MSI-H only
2012 Zaltrap (Ziv-Aflibercept) - mCRC 2nd line,
2012 Stivarga (Regorafenib) - no restrictions
2014 Cyramza (Ramucirumab) - mCRC 2nd line
2015 Lonsurf (Trifluridine and Tipiracil Hydrochloride) - no restrictions
2017 Opdivo (Nivolumab) - mCRC 1st line+, MSI-H only
2018 Yervoy (Ipilimumab) - mCRC 1st line+, MSI-H only
2019 Zirabev (Bevacizumab.alt) - mCRC 1st line+
2020 Braftovi (Encorafenib) - mCRC, BRAF V600E only
Julia123 wrote:good afternoon, i'm from Ukraine, i'm 29 years old, diagnosed on June 4, mucinous adenocarcenoma 3b, now completed the 7th course folfox / 12 tell me who faced this type of tumor? what am I missing in treatment? Maybe I need some other medications and DNA tests? sorry for bad english
Users browsing this forum: Google [Bot] and 4 guests